Alumis Shares Face Pressure as Phase 2b Lupus Trial Fails Primary Endpoints

Key Facts

1Alumis announced that its Phase 2b LUMUS trial of envudeucitinib for SLE did not meet its primary and secondary endpoints.

2The company plans to move forward with Phase 3 development for a specific subgroup of patients who showed robust responses.

3Alumis remains on track to submit an NDA for envudeucitinib in plaque psoriasis in 4Q 2026.

In a move that underscores the significant hurdles biotech firms face in developing treatments for complex immune diseases, Alumis has reported disappointing clinical trial results. According to reports, the Phase 2b LUMUS trial of envudeucitinib for systemic lupus erythematosus (SLE) failed to meet its primary and secondary endpoints in the general patient population. However, the company noted that a specific subgroup of patients exhibited robust responses, leading to plans for Phase 3 development focused exclusively on this segment.

These results arrive at a critical juncture for the pharmaceutical sector as companies compete to validate TYK2 inhibitors for chronic conditions. Despite the setback in the SLE indication, Alumis remains on track to submit a New Drug Application (NDA) for envudeucitinib in plaque psoriasis by the fourth quarter of 2026. The company maintains that pharmacodynamic data continues to support the drug's potential in interferon-driven diseases, per market data and corporate communications.

Operationally, investors are watching how this setback influences the company's long-term pipeline timeline, particularly as authoritative price data for ALMS remains unavailable at this close. Regarding broader catalysts, the market recently processed US Consumer Confidence data, which printed at 89.4 on August 25, 2026. Future regulatory interactions regarding the planned 2026 NDA submission will serve as the next primary catalysts for the stock.